Waldstreicher most recently served as chief medical officer at Johnson & Johnson (NYSE: JNJ) . She held that position from 2012 until her retirement in 2023. As CMO, she provided strategic and operational leadership with responsibility for safety, epidemiology, regulatory and clinical operations. She also oversaw bioethics and late-stage pipeline programs.
Before taking on that role, she served as CMO for Janssen Pharmaceutical R&D, a J&J division, from 2009 to 2012. Prior to that, Waldstreicher was SVP of global drug development from 2002 to 2009. Over her time at J&J, she held responsibilities for clinical research, biostatistics, regulatory affairs and Asia Pacific R&D and medical affairs.
Prior to J&J, Waldstreicher led endocrinology and metabolism clinical research at Merck Research Laboratories.
“Dr. Waldstreicher brings more than 30 years of experience in clinical and strategic leadership roles at some of the leading health care companies in the world,” said Tom Polen, chair, CEO and president of BD. “The combination of her broad experience in R&D, regulatory, clinical evidence generation and safety aligns with BD’s journey to advance our strong innovation agenda, and to be best-in-class for quality and safety in the MedTech industry.”
Waldstreicher also serves on the board of directors of Structure Therapeutics, a publicly traded, clinical-stage biopharmaceutical company. The new BD board member is on an expert panel for the Reagan Foundation for the FDA and is also a faculty affiliate of the Division of Medical Ethics, Department of Population Health at New York University School of Medicine. She serves as an advisory board member of the Brooklyn College Cancer Center.
